Revolution Medicines Presents Updated Zoldonrasib Phase 1 Data for KRAS G12D Lung Cancer at AACR 2026

Key Takeaways

• Revolution Medicines presented updated Phase 1 clinical data for zoldonrasib (RMC-9805) targeting KRAS G12D mutations in lung cancer
• The oral RAS(ON) G12D-selective inhibitor shows promise for previously treated non-small cell lung cancer patients with limited treatment options
• Data presentation at AACR 2026 represents continued advancement in precision oncology for RAS-addicted cancers

---

Revolution Medicines, Inc. (Nasdaq: RVMD) announced updated Phase 1 clinical trial results for zoldonrasib, an investigational oral therapy targeting KRAS G12D mutations in non-small cell lung cancer (NSCLC) patients. The data was presented at the American Association for Cancer Research (AACR) Annual Meeting 2026 in the official press program.

Targeting a Critical Cancer Driver

Zoldonrasib represents a RAS(ON) G12D-selective inhibitor designed specifically for patients whose tumors harbor KRAS G12D mutations. These genetic alterations drive approximately 6-8% of NSCLC cases and have historically been considered “undruggable” until recent therapeutic advances.

The Phase 1 study (RMC-9805-001) focuses on previously treated patients, addressing a significant unmet medical need in advanced lung cancer care. Current treatment options for this patient population remain limited, particularly for those with specific KRAS mutations.

Market Impact and Clinical Significance

Revolution Medicines positions itself as a late-stage clinical oncology company specializing in targeted therapies for RAS-addicted cancers. The company’s focus on precision medicine aligns with growing industry trends toward mutation-specific treatments.

The AACR presentation timing suggests the company is building momentum for potential regulatory discussions. KRAS-targeted therapies represent a rapidly evolving treatment landscape, with several competitors advancing similar approaches.

Looking Forward

The updated clinical data presentation indicates continued patient enrollment and data maturation in the Phase 1 study. Investors and clinicians will likely focus on safety profiles, response rates, and duration of benefit compared to existing standards of care.

Revolution Medicines’ advancement with zoldonrasib reflects broader progress in RAS inhibitor development, potentially offering new hope for patients with historically difficult-to-treat cancers. The company’s targeted approach may position it competitively in the expanding precision oncology market.

---

Frequently Asked Questions

What is zoldonrasib and how does it work?

Zoldonrasib is an oral RAS(ON) G12D-selective inhibitor that specifically targets KRAS G12D mutations found in certain lung cancers. It works by blocking the mutated KRAS protein that drives tumor growth.

When will zoldonrasib be available to patients?

Zoldonrasib is currently in Phase 1 clinical trials. The drug must complete additional clinical phases and receive FDA approval before becoming commercially available, which typically takes several years.

How significant are KRAS G12D mutations in lung cancer?

KRAS G12D mutations occur in approximately 6-8% of non-small cell lung cancer cases. These mutations have been historically difficult to target with drugs, making zoldonrasib’s approach potentially important for this patient population.